Riding high after an Amgen partnership and a $102 million funding round so far this year, Plexium shows no signs of slowing down. Instead, it's inked a new agreement with AbbVie focused on ...
Just weeks after inking a $500 million biobucks pact with Amgen, protein degradation biotech Plexium has secured $102 million in venture capital funds. The preclinical biotech raised the funds to ...
SAN DIEGO--(BUSINESS WIRE)--Plexium today announced the launch of the company with the closing of a $28 million Series A financing. The financing was led by DCVC Bio and The Column Group, with ...
-PLX-61639, a selective, oral SMARCA2 degrader, demonstrated sustained PD response and single-agent efficacy in SMARCA4 mutant tumors; program is advancing through IND-enabling studies- -PLX-4545, a ...
SAN DIEGO, April 2, 2025 /PRNewswire/ -- Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation company, today announced that initial Phase 1 clinical results with PLX-4545, a ...
Amgen and Plexium have announced a research collaboration and licensing agreement to identify and develop new protein degrading treatments for complex diseases. As part of the agreement, Amgen will ...
(RTTNews) - Amgen (AMGN) and Plexium Inc. have entered into multi-year, drug discovery collaboration to identify novel targeted protein degradation therapies. The collaboration combines Plexium's ...
Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day. Subscribe for FREE Leveraging Xavo's rapid deployment capabilities, comprehensive ...
Plexium is the premier, next-generation Targeted Protein Degradation (TPD) company seeking to discover a wide range of monovalent degraders that address the limitations of first-generation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results